Global Nanomedicine Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023

  • ID: 4092019
  • Report
  • Region: Global
  • 93 pages
  • Infoholic Research LLP
1 of 5
The Nanomedicine Market to Grow at a CAGR of 17.1% During the Forecast Period 2017-2023 to Aggregate $392.80 Billion By 2023

FEATURED COMPANIES

  • Amgen Inc
  • Eli Lilly and Company
  • Gilead Sciences
  • Hoffmann-La Roche Ltd
  • Merck & Co.Inc
  • Nanobiotix SA
  • MORE

Overview: Nanomedicine is an offshoot of nanotechnology, and refers to highly-specific medical intervention at the molecular scale for curing diseases or repairing damaged tissues. Nanomedicine uses nano-sized tools for the diagnosis, prevention and treatment of disease, and to gain increased understanding of the complex underlying pathophysiology of the disease. It involves three nanotechnology areas of diagnosis, imaging agents, and drug delivery with nanoparticles in the 1–1,000 nm range, biochips, and polymer therapeutics.

The majority of nanomedicines used now allow oral drug delivery and its demand is increasing significantly. Although these nanovectors are designed to translocate across the gastrointestinal tract, lung, and blood–brain barrier, the amount of drug transferred to the organ is lower than 1%; therefore improvements are challenging. Nanomedicines are designed to maximize the benefit/risk ratio, and their toxicity must be evaluated not only by sufficiently long term in vitro and in vivo studies, but also pass multiple clinical studies.

The major drivers of the nanomedicine market include its application in various therapeutic areas, increasing R&D studies about nanorobots in this segment, and significant investments in clinical trials by the government as well as private sector. The Oncology segment is the major therapeutic area for nanomedicine application, which comprised more than 35% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the nanomedicine market in the future.

Market Analysis: The “Global Nanomedicine Market” is estimated to witness a CAGR of 17.1% during the forecast period 2017–2023. The nanomedicine market is analyzed based on two segments – therapeutic applications and regions.

Regional Analysis: The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (ROW). The Americas is set to be the leading region for the nanomedicine market growth followed by Europe. The Asia Pacific and ROW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various nano-drugs are expected to increase in the coming years. The major countries covered in this report are the US, Germany, Japan, and Others.

Therapeutic Application Analysis: Nanomedicines are used as fluorescent markers for diagnostic and screening purposes. Moreover, nanomedicines are introducing new therapeutic opportunities for a large number of agents that cannot be used effectively as conventional oral formulations due to poor bioavailability. The therapeutic areas for nanomedicine application are Oncology, Cardiovascular, Neurology, Anti-inflammatory, Anti-infectives, and various other areas. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future nano-drugs to be commercially available in the market. The FDA should be relatively prepared for some of the earliest and most basic applications of nanomedicine in areas such as gene therapy and tissue engineering. The more advanced applications of nanomedicine will pose unique challenges in terms of classification and maintenance of scientific expertise.

Key Players: Merck & Co. Inc., Hoffmann-La Roche Ltd., Gilead Sciences Inc., Novartis AG, Amgen Inc., Pfizer Inc., Eli Lilly and Company, Sanofi, Nanobiotix SA, UCB SA and other predominate & niche players.

Competitive Analysis: At present, the nanomedicine market is at a nascent stage – but, a lot of new players are entering the market as it holds huge business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of nanoparticles and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.

Benefits: The report provides complete details about the usage and adoption rate of nanomedicines in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives towards the nanomedicine adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Eli Lilly and Company
  • Gilead Sciences
  • Hoffmann-La Roche Ltd
  • Merck & Co.Inc
  • Nanobiotix SA
  • MORE
1 Industry Outlook
1.1 Industry Overview
1.2 Industry Trends
1.3 PEST Analysis

2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions

3 Market Snapshot
3.1 Total Addressable Market (TAM)
3.2 Segmented Addressable Market (SAM)
3.3 Related Markets
3.3.1 mHealth Market
3.3.2 Healthcare Analytics Market

4 Market Outlook
4.1 Overview
4.2 Regulatory Bodies and Standards
4.3 Government Spending and Initiatives
4.4 Porter 5 (Five) Forces

5 Market Characteristics
5.1 Evolution
5.2 Ecosystem
5.2.1 Regulatory Process
5.2.2 Clinical Trials
5.2.3 Pricing and Reimbursement
5.3 Market Segmentation
5.4 Market Dynamics
5.4.1 Drivers
5.4.1.1 Emergence of nanorobotics
5.4.1.2 Applications and advantages of nanomedicine in various healthcare segments
5.4.1.3 Reasonable investments in R&D
5.4.1.4 Increased support from governments
5.4.2 Restraints
5.4.2.1 Long approval process and stringent regulations
5.4.2.2 Problems regarding nanoscale manufacturing
5.4.2.3 Risks related to nanomedicines
5.4.2.4 Undefined regulatory standards
5.4.3 Opportunities
5.4.3.1 Aging population with chronic care needs
5.4.3.2 Population and income growth in emerging countries
5.4.4 DRO - Impact Analysis

6 Trends, Roadmap and Projects
6.1 Market Trends and Impact
6.2 Technology Roadmap

7 Types: Market Size and Analysis
7.1 Overview
7.2 Global Nanomedicine Market in Oncology Segment
7.3 Global Nanomedicine Market in Cardiovascular Segment
7.4 Global Nanomedicine Market in Neurology Segment
7.5 Global Nanomedicine Market in Anti-inflammatory Segment
7.6 Global Nanomedicine Market in Anti-infective Segment
7.7 Global Nanomedicine Market in Other Therapeutic Areas

8 Trending Nanomedicines
8.1 Overview
8.2 Abraxane
8.3 Alimta
8.4 Eligard
8.5 Copaxone
8.6 Rapamune
8.7 Neulasta
8.8 Cimzia
8.9 AmBisome
8.10 Mircera
8.11 Pegasys
8.12 Emend
8.13 Renagel
8.14 Ritalin

9 Regions: Market Size and Analysis
9.1 Overview
9.1.1 Global Nanomedicine Market by Geographical Segmentation
9.2 Key Leading Countries
9.2.1 US
9.2.2 Germany
9.2.3 Japan

10 Vendor Scenario

11 Vendor Profiles
11.1 Merck & Co. Inc.
11.1.1 Overview
11.1.2 Business Unit
11.1.3 Geographic Revenue
11.1.4 Recent Developments
11.1.5 SWOT Analysis
11.1.6 Business Strategies
11.2 Hoffmann-La Roche Ltd.
11.2.1 Overview
11.2.2 Business Unit
11.2.3 Geographic Revenue
11.2.4 Recent Developments
11.2.5 SWOT Analysis
11.2.6 Business Strategies
11.3 Gilead Sciences
11.3.1 Overview
11.3.2 Business Unit
11.3.3 Geographic Revenue
11.3.4 Recent Developments
11.3.5 SWOT Analysis
11.3.6 Business strategies
11.4 Novartis AG
11.4.1 Overview
11.4.2 Business Unit
11.4.3 Geographic Revenue
11.4.4 Recent Developments
11.4.5 SWOT Analysis
11.4.6 Business Strategies
11.5 Amgen Inc.
11.5.1 Overview
11.5.2 Business Unit
11.5.3 Geographic Revenue
11.5.4 Recent Developments
11.5.5 SWOT Analysis
11.5.6 Business Strategies

12 Global Generalist
12.1 Pfizer Inc.
12.1.1 Overview
12.1.2 Recent Developments
12.1.3 Pfizer in 2015
12.2 Eli Lilly and Company
12.2.1 Overview
12.2.2 Recent Developments
12.2.3 Eli Lilly and Company in 2015
12.3 Sanofi
12.3.1 Overview
12.3.2 Recent Developments
12.3.3 Sanofi in 2015

13 Companies to Watch for
13.1 Nanobiotix SA
13.1.1 Overview
13.1.2 Offering
13.1.3 Recent Developments
13.2 UCB SA
13.2.1 Overview
13.2.2 Offering
13.2.3 Recent Developments

14 Market Landscape
14.1 Market Landscape
14.1.1 Mergers & Acquisitions (M&A)
Annexure
Abbreviations
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amgen Inc
  • Eli Lilly and Company
  • Gilead Sciences
  • Hoffmann-La Roche Ltd
  • Merck & Co.Inc
  • Nanobiotix SA
  • Novartis AG
  • Pfizer Inc
  • Sanofi
  • UCB SA.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll